Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
暂无分享,去创建一个
Carl H. June | Yangbing Zhao | C. June | Xiaojun Liu | Shuguang Jiang | C. Fang | Yangbing Zhao | Jiangtao Ren | Shuguang Jiang | Xiaojun Liu | Chongyun Fang | Jiangtao Ren
[1] David Bryder,et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. , 2014, Cell stem cell.
[2] Alan Maréchal,et al. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[4] Aymeric Duclert,et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.
[5] B. van Steensel,et al. Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.
[6] E. Leiter,et al. Major Histocompatibility Complex Class I-Deficient NOD-B2mnull Mice are Diabetes and Insulitis Resistant , 1994, Diabetes.
[7] Jin-Soo Kim,et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases , 2014, Genome research.
[8] A. Wu,et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.
[9] B. Levine,et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.
[10] Norman L. Letvin,et al. In Vivo Natural Killer Cell Depletion during Primary Simian Immunodeficiency Virus Infection in Rhesus Monkeys , 2008, Journal of Virology.
[11] D. Dolfi,et al. Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors , 2014, Clinical Cancer Research.
[12] David A. Scott,et al. Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.
[13] R. Shattock,et al. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. , 2015, The Journal of general virology.
[14] S. Rosenberg,et al. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[15] S. Grupp,et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. , 2011, Human gene therapy.
[16] Luigi Naldini,et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. , 2012, Blood.
[17] Wei-Ting Hwang,et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.
[18] Randall J. Platt,et al. Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.
[19] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[20] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[21] I. Pastan,et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.
[22] J. Orange,et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.
[23] W. Wilson,et al. Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.
[24] Jennifer A. Doudna,et al. Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease , 2010, Science.
[25] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[26] D. Atanackovic,et al. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer , 2014, Gene Therapy.
[27] Lei Zhang,et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.
[28] Yi Li,et al. High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1 , 2007, The Journal of Immunology.
[29] Yu Chen,et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection , 2015, Scientific Reports.
[30] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[31] M. Smyth,et al. Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells , 2013, Clinical Cancer Research.
[32] C. van Broeckhoven,et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.
[33] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[34] Di Zhang,et al. CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection , 2014, PloS one.
[35] N. Letvin,et al. Use of an anti‐CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques , 2008, Immunology.
[36] J. Joung,et al. High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.
[37] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W. Burns,et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. , 2014, Human gene therapy.
[39] Andrew Sewell,et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines , 2005, The Journal of experimental medicine.
[40] J. Keith Joung,et al. High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.
[41] Rudolf Jaenisch,et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. , 2013, Blood.
[42] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.